STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Aniridia
- Focus Adverse reactions; Proof of concept
- Acronyms STAR
- Sponsors PTC Therapeutics
- 02 Aug 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
- 02 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2019.
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.